Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. BAC

Go back to Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
(NASDAQ: XENE) Delayed: 59.75 -0.65 (1.08%)
Previous Close $60.40    52 Week High $9.75 
Open $60.02    52 Week Low $5.65 
Day High $60.57    P/E N/A 
Day Low $59.43    EPS $0.00 
Volume 459,232       

(NASDAQ: XENE) Delayed: 59.75 -0.65 (1.08%)
Previous Close $60.40    52 Week High $9.75 
Open $60.02    52 Week Low $5.65 
Day High $60.57    P/E N/A 
Day Low $59.43    EPS $0.00 
Volume 459,232